Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
July 01 2021 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced the appointment of Esther M. Alegria,
Ph.D., as an independent member of the company’s board of
directors. Dr. Alegria has nearly 30 years of biopharmaceutical
industry experience spanning research and development,
manufacturing, quality control, assurance and compliance,
technology transfer and regulatory submissions supporting the
development and commercialization of small and large molecule
therapeutics and vaccines.
“I am happy to express the board’s excitement in
welcoming Dr. Alegria as a new director,” said Joseph Carleone,
Ph.D., Avid’s chairman of the board. “We are all looking forward to
working alongside Dr. Alegria and tapping into her vast biopharma
industry expertise.”
“Dr. Alegria has a broad and impressive
professional background with experience that spans every aspect of
the biopharmaceutical industry that is relevant to Avid’s CDMO
business. This includes a former tenure at Biogen where she most
recently served as senior vice president of global manufacturing,
and oversaw the manufacturing of a wide range of products including
large-scale drug substances, as well as small molecule
therapeutics, in world-class facilities around the globe,” said
Nicholas Green, president and chief executive officer of Avid
Bioservices. “The array of insight and guidance that she will be
able to impart on our team based on her track record of success
will be invaluable as we continue to execute against our growth
strategy for the business.”
Dr. Alegria said, “I am thrilled to have the
opportunity to join the Avid board, which I believe is one of the
most accomplished collection of directors within the CDMO industry.
Avid has made great strides over the past few years in establishing
itself as a leader in this space and I am excited to offer the team
my experience to support the company’s continued growth.”
Dr. Alegria currently serves as the chief
executive officer of APIE Therapeutics, leading a team of seasoned
industry experts focused on advancing novel treatments for
idiopathic pulmonary fibrosis and heart failure toward clinical
development. Prior to joining APIE, she was president and senior
executive biopharmaceutical advisor at Catalyst Excel &
Advance, an advisory firm providing operational guidance to senior
executives working to launch new pharmaceutical and
biopharmaceutical companies. In this role, Dr. Alegria leveraged
her nearly 30 years of experience in research and development
through commercialization to offer counsel to executives on topics
including manufacturing, quality and process
development.
She previously served as senior vice president
of global manufacturing at Biogen, where she was responsible for
the company’s successful manufacturing operations in Denmark,
Massachusetts and North Carolina. These facilities covered the
production of large-scale drug substances, medical device
assemblies, finished goods, and small-molecule manufacturing
operations. Dr. Alegria has also held positions of increasing
responsibility in the R&D Wyeth Organization (now Pfizer),
where she earned the company award for analytical technology in the
development and launch of Prevnar. She holds a Ph.D. in chemistry
from the University of Hawaii and an executive business management
certification from Harvard Business School.
About Avid Bioservices,
Inc.Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical drug
substances derived from mammalian cell culture. The company
provides a comprehensive range of process development, CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 28 years of
experience producing monoclonal antibodies and recombinant
proteins, Avid's services include CGMP clinical and commercial drug
substance manufacturing, bulk packaging, release and stability
testing and regulatory submissions support. For early-stage
programs the company provides a variety of process development
activities, including upstream and downstream development and
optimization, analytical methods development, testing and
characterization. The scope of our services ranges from standalone
process development projects to full development and manufacturing
programs through commercialization. www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024